drugset
drugset / Trial / NCT04722978

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

NCT04722978 ↗

Phase 3 Recruiting 228 enrolled Sun Yat-sen University Cancer Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic triple-negative breast cancer randomised to treatment with standard chemotherapy plus moxifloxacin or placebo.

Timeline

Start
2021-04-20
Primary completion
2026-06
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 0.4 unknown Oral
Comparator Carboplatin Small molecule 2 unknown Intravenous
Comparator Gemcitabine Small molecule 1000 mg/m2 Intravenous

Indications

triple-negative breast carcinoma